Raiffeisen Bank International’s Intellia Therapeutics NTLA Stock Holding History

Raiffeisen Bank International’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,000	Closed	-$24.6K	–	877
2025 Q2	$18.8K	Hold	2,000	–	–	﹤0.01%	530
2025 Q1	$14.2K	Hold	2,000	–	–	﹤0.01%	548
2024 Q4	$23.7K	Buy	+2,000	New	+$31.2K	﹤0.01%	539

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raiffeisen Bank International's NTLA Position: Q3 2025 in Review

Raiffeisen Bank International sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 2,000 shares — an estimated $24.6K sold.

Raiffeisen Bank International first reported a position in NTLA in Q4 2024 and held it in 3 quarters. The position peaked at $23.7K in Q4 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

Raiffeisen Bank International reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
Raiffeisen Bank International sold 2,000 Intellia Therapeutics shares in Q3 2025, an estimated $24.6K.
Raiffeisen Bank International first reported a position in Intellia Therapeutics in Q4 2024 and held it in 3 quarters.
Raiffeisen Bank International's Intellia Therapeutics position peaked at $23.7K in Q4 2024.
283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Raiffeisen Bank International's 13F filing for Q3 2025, filed 10 Nov 2025.